Holger H H Erb

List of Publications by Year
in descending order

41 papers	986 citations	777949 13 h-index	488211 31 g-index
42 all docs	42 docs citations	42 times ranked	2052 citing authors

#	Article	IF	Citations
1	Impact of Androgen Receptor Activity on Prostate-Specific Membrane Antigen Expression in Prostate Cancer Cells. International Journal of Molecular Sciences, 2022, 23, 1046.	1.8	4
2	The Androgen Hormone-Induced Increase in Androgen Receptor Protein Expression Is Caused by the Autoinduction of the Androgen Receptor Translational Activity. Current Issues in Molecular Biology, 2022, 44, 597-608.	1.0	5
3	Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines. Journal of Cancer Research and Clinical Oncology, 2022, , 1.	1.2	1
4	Influence of Systemic Therapy on the Expression and Activity of Selected STAT Proteins in Prostate Cancer Tissue. Life, 2022, 12, 240.	1.1	1
5	Physiological and Genetically Engineered Expression Modulation Methods Do Not Affect Cellular Levels of the Heat Shock Protein HSP60 in Prostate Cancer Cells. In Vivo, 2022, 36, 596-602.	0.6	1
6	Systemic Triple Therapy in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Ready for Prime Time or Still to Be Explored?. Cancers, 2022, 14, 8.	1.7	12
7	IL-4 Counteracts the Cytotoxic Effects of Peripheral Blood Mononuclear Cells on Hormone-sensitive Prostate Cancer Cells. In Vivo, 2021, 35, 1973-1977.	0.6	1
8	Gelsolin Governs the Neuroendocrine Transdifferentiation of Prostate Cancer Cells and Suppresses the Apoptotic Machinery. Anticancer Research, 2021, 41, 3717-3729.	0.5	6
9	Enzalutamide-induced Proteolytic Degradation of the Androgen Receptor in Prostate Cancer Cells Is Mediated Only to a Limited Extent by the Proteasome System. Anticancer Research, 2021, 41, 3271-3279.	0.5	7
10	A Systematic Comparison of Antiandrogens Identifies Androgen Receptor Protein Stability as an Indicator for Treatment Response. Life, 2021, 11, 874.	1.1	8
11	Impact of STAT Proteins in Tumor Progress and Therapy Resistance in Advanced and Metastasized Prostate Cancer. Cancers, 2021, 13, 4854.	1.7	12
12	Non-Invasive Physical Plasma Enhances the Membrane Permeability to Low Molecular Weight Compounds and Subsequently Leads to the Loss of Cellular ATP and the Devitalization of Epithelial Cancer Cells. Applied Sciences (Switzerland), 2021, 11, 9801.	1.3	2
13	Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer. PLoS ONE, 2020, 15, e0237248.	1.1	11
14	Soluble heat-shock protein 27 in blood serum is a non-invasive prognostic biomarker for ovarian cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 255, 154-159.	0.5	2
15	Re: Maria J. Ribal, Philip Cornford, Alberto Briganti, et al. European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.056. European Urology Focus, 2020, 6, 1135-1136.	1.6	9
16	AR-V7 Protein Expression in Circulating Tumour Cells Is Not Predictive of Treatment Response in mCRPC. Urologia Internationalis, 2020, 104, 253-262.	0.6	4
17	Abstract 6327: Artesunate reduces tumor growth and induces different kinds of cell death in docetaxel-resistant prostate carcinoma cells. , 2020, , .		0
18	Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer. , 2020, 15, e0237248.		0

#	Article	IF	Citations
19	Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer. , 2020, 15, e0237248.		0
20	Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer. , 2020, 15, e0237248.		0
21	The androgen receptor antagonist enzalutamide induces apoptosis, dysregulates the heat shock protein system, and diminishes the androgen receptor and estrogen receptor Î²1 expression in prostate cancer cells. Journal of Cellular Biochemistry, 2019, 120, 16711-16722.	1.2	16
22	PIAS1 is not suitable as a urothelial carcinoma biomarker protein and pharmacological target. PLoS ONE, 2019, 14, e0224085.	1.1	2
23	The putative tumour suppressor protein Latexin is secreted by prostate luminal cells and is downregulated in malignancy. Scientific Reports, 2019, 9, 5120.	1.6	11
24	Resolution of Cellular Heterogeneity in Human Prostate Cancers: Implications for Diagnosis and Treatment. Advances in Experimental Medicine and Biology, 2019, 1164, 207-224.	0.8	7
25	Interleukinâ€4 induces a CD44_{high}/CD49b_{high} PC3 subpopulation with tumorâ€initiating characteristics. Journal of Cellular Biochemistry, 2018, 119, 4103-4112.	1.2	10
26	The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models. Molecular Cancer Therapeutics, 2018, 17, 2722-2731.	1.9	32
27	Fractionated Radiation of Primary Prostate Basal Cells Results in Downplay of Interferon Stem Cell and Cell Cycle Checkpoint Signatures. European Urology, 2018, 74, 847-849.	0.9	4
28	Relevance of the natural HDAC inhibitor sulforaphane as a chemopreventive agent in urologic tumors. Cancer Letters, 2018, 435, 121-126.	3.2	22
29	The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling. Oncogenesis, 2017, 6, e342-e342.	2.1	68
30	SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells. Molecular Cancer Research, 2016, 14, 574-585.	1.5	36
31	Inhibition of the glucocorticoid receptor results in an enhanced miR-99a/100-mediated radiation response in stem-like cells from human prostate cancers. Oncotarget, 2016, 7, 51965-51980.	0.8	35
32	Therapy escape mechanisms in the malignant prostate. Seminars in Cancer Biology, 2015, 35, 133-144.	4.3	59
33	Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy. Oncotarget, 2015, 6, 6105-6122.	0.8	28
34	IL6 sensitizes prostate cancer to the antiproliferative effect of IFNÎ±2 through IRF9. Endocrine-Related Cancer, 2013, 20, 677-689.	1.6	25
35	Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. Endocrine-Related Cancer, 2012, 19, 305-319.	1.6	56
36	Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and Is Mediated by Reduced Expression of miR-200c and miR-205. American Journal of Pathology, 2012, 181, 2188-2201.	1.9	225

#	Article	IF	Citations
37	PIAS1 Is Increased in Human Prostate Cancer and Enhances Proliferation through Inhibition of p21. American Journal of Pathology, 2012, 180, 2097-2107.	1.9	72
38	Inhibition of the Acetyltransferases p300 and CBP Reveals a Targetable Function for p300 in the Survival and Invasion Pathways of Prostate Cancer Cell Lines. Molecular Cancer Therapeutics, 2011, 10, 1644-1655.	1.9	188
39	Abstract 1622: Inhibition of the acetyltransferase p300 as a novel pro-apoptotic and anti-invasion approach for treatment of prostate cancer. , 2011, , .		1
40	Abstract 1711: Establishment and characterization of docetaxel resistant prostate cancer cell lines. , 2011, , .		0
41	Influence of Androgen Deprivation Therapy on the PD-L1 Expression and Immune Activity in Prostate Cancer Tissue. Frontiers in Molecular Biosciences, 0, 9, .	1.6	3